Posted by Michael Wonder on 04 Mar 2022
BeiGene announces Health Canada approval for Brukinsa (zanubrutinib) in relapsed or refractory marginal zone lymphoma
3 March 2022 - Third approved indication for Brukinsa in Canada, following mantle cell lymphoma and Waldenström’s macroglobulinaemia.
BeiGene today announced that Brukinsa (zanubrutinib) has been approved by Health Canada for the treatment of adult patients with marginal zone lymphoma who have received at least one prior anti-CD20-based therapy.
